Logo

Horizon Initiates P-III (OPTIC-J) Trial of Teprotumumab for the Treatment of Active Thyroid Eye Disease

Share this

Horizon Initiates P-III (OPTIC-J) Trial of Teprotumumab for the Treatment of Active Thyroid Eye Disease

Shots:

  • The 1st patient has been enrolled in a P-III (OPTIC-J) trial to evaluate the efficacy, tolerability & safety of teprotumumab vs PBO in a ratio (1:1) in 50 adults with active TED across the US & EU
  • The primary efficacy EPs is proptosis response rate @24wks. & also evaluates ORR, change from baseline in proptosis measurement, diplopia responder rate & change from baseline in the GO-QoL questionnaire @24wks.
  • Additionally, patients will enter an OLE period to receive an additional 8 infusions of teprotumumab @24wks. during the 48wk. follow-up, following the completion of the treatment period & proptosis non-responders. The therapy has been marketed under the brand name Tepezza in the US

 Ref: Horizon | Image: Horizon

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions